Skip to main content
. 2021 Mar 18;3(4):227–233. doi: 10.1253/circrep.CR-21-0013

Table 1.

Clinical Characteristics at Baseline and at the End of the Study Period

Parameter Baseline End of the study period P value
Age (years) 45±9 48±9 <0.01
BMI (kg/m2) 24.0±3.0 24.2±3.1 <0.01
Current smoking 543 (29) 456 (24) <0.01
SBP (mmHg) 123±14 121±14 <0.01
Heart rate (beats/min) 69±10 68±10 <0.01
Uric acid (mg/dL) 6.2±1.2 6.1±1.2 <0.01
Hemoglobin (g/L) 14.9±1.0 14.6±0.9 <0.01
LDL-C (mg/dL) 129±31 128±32 0.63
HDL-C (mg/dL) 63±16 65±16 <0.01
TG (mg/dL) 130±118 125±90 0.02
Serum creatinine (mg/dL) 0.88±0.48 0.85±0.39 <0.01
HbA1c (%) 5.2±0.5 5.1±0.6 <0.01
Serum NT-proBNP (pg/mL) 18 [8–31] 24 [14–38] <0.01
baPWV (cm/s) 1,291±187 1,317±203 <0.01
Ankle brachial index 1.14±0.73 1.15±0.71 0.01
PEP/ET ratio 0.35 [0.32–0.38] 0.36 [0.32–0.39] <0.01
Medication history
 Hypertension 172 (9) 261 (14) <0.01
 Dyslipidemia 67 (4) 115 (6) <0.01
 Diabetes 51 (3) 73 (4) <0.01
 Hyperuricemia 68 (4) 81 (4) <0.01

Continuous variables are presented as the mean±SD if normally distributed and as the median [interquartile range] if not; categorical variables are presented as n (%). baPWV, brachial-ankle pulse wave velocity; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NT-proBNP, N-terminal pro B-type natriuretic peptide; PEP/ET, pre-ejection period/ejection time; SBP, systolic blood pressure; TG, triglyceride.